Meningococcal vaccine groups A C Y W-135 conjugate - Novartis
Alternative Names: GSK3536820A; MCV4 vaccine; MenACWY-CRM; Menhycia; Menveo; Multivalent ACWY vaccine candidate - NovartisLatest Information Update: 01 Oct 2024
At a glance
- Originator Novartis
- Developer GSK; Novartis; Tianjin CanSino Biotechnology
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Meningococcal infections
Most Recent Events
- 22 Jul 2024 GSK completes the phase-III MENB REC 2ND GEN-045 (V72_79) trial in Meningococcal infections (In adolescents, Prevention) in USA and Italy (IM), (NCT04318548),
- 26 Jan 2024 CanSino Biologics plans a phase III trial for Meningococcal infections (Prevention) (IM, Injection), in March 2024 (NCT06226714)
- 14 Nov 2023 CanSino Biologics plans a phase III trial for Meningococcal infections in Indonesia (IM, Injection) in December 2023 (NCT06131554)